The Ministry of Justice is committed to improving support for neurodivergent individuals, including those with ADHD, across the criminal justice system.

We recognise the importance of early identification of individuals’ needs. As part of the Neurodiversity Action Plan, HMCTS has developed a signposting strategy to help court and tribunal users with additional needs to access support. HMPPS take a needs-led approach to supporting neurodivergent individuals and now screens all prisoners upon arrival. It has introduced a new Additional Learning Needs screener as part of the new Prisoner Education Service. This allows HMPPS to identify any needs and inform appropriate support and reasonable adjustments in order to help prisoners engage with education, skills, work and rehabilitation opportunities.

We continue to work with partners, including the Department of Health and Social Care (DHSC) through the Health and Justice National Neurodiversity Programme Board, building on progress highlighted in the final update to the Cross-Government Neurodiversity Action Plan, published in February 2026. Our approach draws on the wider recommendations of NHS England's Independent ADHD taskforce and the Chief Medical officer's report on the health of people in prison and on probation, which included a focus on neurodiversity. We have no current plans to establish a separate Taskforce.

The Ministry of Justice is committed to improving support for neurodivergent individuals, including those with ADHD, across the criminal justice system.

We recognise the importance of early identification of individuals’ needs. As part of the Neurodiversity Action Plan, HMCTS has developed a signposting strategy to help court and tribunal users with additional needs to access support. HMPPS take a needs-led approach to supporting neurodivergent individuals and now screens all prisoners upon arrival. It has introduced a new Additional Learning Needs screener as part of the new Prisoner Education Service. This allows HMPPS to identify any needs and inform appropriate support and reasonable adjustments in order to help prisoners engage with education, skills, work and rehabilitation opportunities.

We continue to work with partners, including the Department of Health and Social Care (DHSC) through the Health and Justice National Neurodiversity Programme Board, building on progress highlighted in the final update to the Cross-Government Neurodiversity Action Plan, published in February 2026. Our approach draws on the wider recommendations of NHS England's Independent ADHD taskforce and the Chief Medical officer's report on the health of people in prison and on probation, which included a focus on neurodiversity. We have no current plans to establish a separate Taskforce.

We know that people are waiting too long for community services. That is why, for the first time, we have set a clear target for systems to work to reduce long waits. By 2028/29, at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care.

In 2025, we published Standardising Community Health Services which provides an overview of core community health services. Setting clear expectations of the core community health services, integrated care boards will support consistent delivery of community health services and effective commissioning, and will improve patient access to care.

NHS England works with local systems, including integrated care boards, to manage demand and mitigate the impact of waiting times on patients, particularly in areas of highest clinical risk. Community health services waiting time data is monitored nationally through NHS England's monthly Community Health Services Situation Report.

The Government is deeply concerned that too many adults, children, and young people with attention deficit hyperactivity disorder (ADHD) and autism are not getting the support they need early enough, consistently enough, or in ways that are well matched to their needs. There is a range of cross-Government work underway that is examining the impacts of neurodevelopmental conditions on health, education, and employment, and how people can be supported earlier and more effectively.

In December 2025, the Government launched an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.

We are also committed to transforming outcomes for children, young people, and their families with special educational needs and disabilities (SEND) through pivotal reforms. We want these reforms to support the treatment to prevention shift in our 10-Year Health Plan and its focus on early identification of needs, support, and intervention, enabling more children to access support and thrive in inclusive mainstream settings.

Central to this is the new Experts at Hand offer, backed by £1.8 billion over three years, which will bring health and education professionals around mainstream settings. Alongside this, £1.6 billion will be invested over the next three years to make the mainstream system more inclusive, building on the latest evidence and practice. By 2028, up to £15 million will have been invested to build the evidence base for, and then provide, national inclusion standards. These will set out, for the first time, what support should be available in every mainstream setting. We will also refresh areas of need, update guidance on reasonable adjustments, and revise the SEND Code of Practice.

The Timms Review, the first review of the Personal Independence Payment benefit, is examining how it can better support disabled people to live independently and access the right support at the right level. The review is due to report in the autumn. Additionally, the Milburn Review on Young People and Work is examining how health conditions can affect participation in education, employment, and training, and the implications for welfare dependency. It published its interim report on 28 May, with the final report due to be published later this year.

The Government will consider the findings of these reviews to inform future Government decisions.

The investment in focal therapies, announced on 2 June 2026, will strengthen existing provision in line with the expansion of the TRANSFORM trial for prostate cancer screening.

Any expansion of focal therapy provision to new sites will include appropriate clinical and market engagement. Officials at the Department are working closely with clinicians and researchers to optimise the planned investment of up to £2.8 million in focal therapy. Further details of this investment will be announced in due course.

The Government itself has not made an overall economic assessment of the impact of attention deficit hyperactivity disorder (ADHD) and neurodivergence. However, the independent ADHD Taskforce, which reported in 2025, reported that currently the estimated economic costs of not treating ADHD are approximately £17 billion to the United Kingdom’s economy. Three relevant ongoing reviews will help the Government better understand the issues and how they could be addressed.

The Government announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.

The next stage of the review will look at service design and how services might respond more effectively to rising need, including the role of earlier intervention, community-based provision, and more integrated pathways across health, education, and other public services. The review will also look at the question of what role the private sector plays in diagnostic services.

The Timms Review, the first review of the Personal Independence Payment benefit, is examining how it can better support disabled people to live independently and access the right support at the right level. It published its interim report on 15 July 2026, with the final review due to report in the autumn. Additionally, the Milburn Review on Young People and Work is examining how health conditions, including ADHD and autism, can affect participation in education, employment, and training, and the implications for welfare dependency. It published its interim report on 28 May, with the final report due to be published later this year. The Government will consider the findings from these reviews, alongside those of the Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism.

The information requested is not held or routinely published.

The UK Health Security Agency’s (UKHSA) English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) publishes surveillance data on antibiotic-resistant infections, including estimates of 30-day all-cause mortality following resistant bloodstream infections. However, these figures are not a measure of deaths attributable to antimicrobial resistance and should not be interpreted as deaths caused by antibiotic-resistant infections. This surveillance data is available on the GOV.UK website.

The UKHSA publishes case-fatality statistics for healthcare-associated infections, which are available on the GOV.UK website, including methicillin-resistant staphylococcus aureus. However, these cannot be used to determine deaths attributable to antibiotic resistance because they do not distinguish the effect of resistance from other factors such as underlying illness, age, comorbidities, or the infection itself.

There is no breakdown of the statistics by National Health Service estate.

The ESPAUR’s 2024 to 2025 report included a breakdown by hospital- and community-onset infection but did not include place of death and cannot determine the proportion of deaths occurring in hospital.

The UKHSA is now developing the capability to produce annual estimates of deaths attributable to antibiotic-resistant bloodstream infections as part of the United Kingdom’s 2024 to 2029 national action plan for antimicrobial resistance, which is available on the GOV.UK website.

VAT is a broad-based tax on consumption, with a 20 per cent standard rate applying to most goods and services on the price paid. As such, if accommodation providers increase their prices in response to the levy, VAT will apply to the entirety of the higher price.

Local authorities wishing to introduce a visitor levy scheme have several flexibilities they can use, including the rate the levy is set at and discretion over which businesses are in scope.

VAT reliefs come at a cost to the Exchequer and have to represent value for money for taxpayers as a whole. The Government keeps all taxes under review and any decisions on tax policy are taken at the Autumn Budget.

The Government recognises the significant contribution made by hospitality businesses to economic growth and social life in the UK and has introduced new permanently lower business rates multipliers for eligible retail, hospitality and leisure properties. These new multipliers are worth nearly £1 billion per year and benefit over 750,000 properties.

The precise design and scope of the overnight visitor levy power are still under development, and its impacts will largely be determined by local decisions. The government will respond to the consultation shortly. Evidence from international and domestic schemes suggests that modest rates have minimal impact on visitor numbers.

Mayors and local leaders will decide whether to introduce a levy. As part of that process, they will be required to consult and consider the impacts on businesses and others.

The precise design and scope of the overnight visitor levy power are still under development, and its impacts will largely be determined by local decisions. The government will respond to the consultation shortly. Evidence from international and domestic schemes suggests that modest rates have minimal impact on visitor numbers.

Mayors and local leaders will decide whether to introduce a levy. As part of that process, they will be required to consult and consider the impacts on businesses and others.

The precise design and scope of the overnight visitor levy power are still under development, and its impacts will largely be determined by local decisions. The government will respond to the consultation shortly. Evidence from international and domestic schemes suggests that modest rates have minimal impact on visitor numbers.

Mayors and local leaders will decide whether to introduce a levy. As part of that process, they will be required to consult and consider the impacts on businesses and others.

National survival data for malignant brain cancers is collected and monitored. The latest available data for England shows one-year net survival for malignant brain cancer was 44%, and five-year net survival was 16.4%.

The Department recognises that outcomes for people with brain tumours, including glioblastoma, remain poor, and that people living in more deprived areas are more likely to be diagnosed later and experience poorer cancer outcomes. Tackling health inequalities across the cancer pathway, including inequalities linked to deprivation, ethnicity, and geography, is a core priority of the National Cancer Plan for England.

Through the National Cancer Plan, the Government is committed to improving earlier diagnosis, reducing variation in access and outcomes, and strengthening care for people with rare and less survivable cancers, including glioblastoma. Glioblastoma is recognised as a rare and aggressive cancer with limited treatment options, and we continue to support research and innovation, including in genomics, clinical trials, and precision medicine.

The National Cancer Plan, published on 4 February 2026, sets out several actions and commitments on immunotherapies, to be delivered within the next ten years. Working alongside the 10-Year Health Plan, the National Cancer Plan aims to ensure wider access to advanced treatments, to personalise cancer treatment for all who need it.

The plan sets out how access to advanced treatments and personalised medicine, supported by genomic testing, will be sped up and widened. This includes a commitment to expand access to targeted and personalised therapies, such as Chimeric Antigen Receptor (CAR-T) cell therapy, alongside ongoing work on mRNA vaccines.

The creation and roll out of the next generation of personalised treatments is a significant commitment set out in the Plan. New technologies, including artificial intelligence, molecular radiotherapy, genomics, alongside mRNA vaccines, offer the possibility of greater advances. Ongoing work on genomics will support the development of new treatments that have the best opportunity of curing an individual’s specific cancer and preventing its recurrence. Progress in cancer vaccines through the Vaccine Innovation Pathway and Cancer Vaccine Launch Pad (CVLP) and will deliver up to 10,000 cancer vaccines by 2030.

The CVLP is a platform that is increasing access and speeding up recruitment to clinical trials for personalised cancer vaccines and other immunotherapies for patients who have been diagnosed with cancer. In 2025, the scope of the CVLP was expanded beyond personalised cancer vaccines to also include other immunotherapies. NHS England is responsible for the overall delivery of the CVLP and has contracted Southampton Clinical Trials Unit to manage the day-to-day delivery of the platform. The platform is designed to be company and clinical trial agnostic so any company can contact the CVLP to explore how the platform can support their research.

Together with our international partners, we have already imposed on Russia the largest and most severe package of sanctions ever imposed on a major economy, but we continue to keep our sanctions regimes, measures and effectiveness under constant review and adapt them to respond to evolving risks.

UK financial sanctions prohibit making funds or economic resources available, directly or indirectly, to designated persons, including sanctioned Russian banks, and prohibit circumvention of these measures. All UK entities are required to comply, supported by robust enforcement across government, but it is our long-standing policy not to comment on individual companies or investments.

Together with our international partners, we have already imposed on Russia the largest and most severe package of sanctions ever imposed on a major economy, but we continue to keep our sanctions regimes, measures and effectiveness under constant review and adapt them to respond to evolving risks.

UK financial sanctions prohibit making funds or economic resources available, directly or indirectly, to designated persons, including sanctioned Russian banks, and prohibit circumvention of these measures. All UK entities are required to comply, supported by robust enforcement across government, but it is our long-standing policy not to comment on individual companies or investments.

Information on the number of patients who waited more than four hours from a decision to admit to admission and subsequently self-discharged before admission is not held centrally.